fbpx
Connect with us

BUSINESS

Maricann Group Inc (OTCMKTS:MRRCF) Reveals Details Of Malta Enterprise, Management Expansion & Clinical Trials

Published

on

Maricann Group Inc (OTCMKTS:MRRCF) recently revealed details about the Letter Of Intent (LOI) for acquiring license from the authorities in Malta. The company also revealed updates related to its latest clinical trials and the decision to expand its management.

Maricann hoping to receive approval for license

As per the reports, after discussing things with Malta Enterprise, the government authority that supervises the issuance of such license, Maricann has now applied for the license. Simultaneously, the company has also terminated the Letter Of Intent for acquiring Medican Holdings. Prior to these developments, Medican was the first to receive the initial approval whereas Maricann had received confirmation for it.

Later on Malta Enterprise communicated with Maricann and asked the company to request Medican to file its own application as they wanted to work with Maricann instead of Medican. That is why Maricann has now decided to submit its own application and now Malta Enterprise has even acknowledged it by giving the receipt. The company is hoping that the application will be reviewed in a period of one month and the decision will be in its favor.

Maricann aspires to expand medical testing in Europe

The Medical Cannabis Market in Europe has been expanding rapidly which is why Maricann has decided to focus its attention on the European cannabis market. Recently, the company announced that it is expanding its management team in the Europe with the intention to expand its ability to fulfill medical testing in the continent. According to reports, Maricann is planning to divert its focus of medical marijuana research and development in Germany.

As a part of its expansion process, the company recently appointed Morten Lars Brandt as the General Manager for Maricann in Europe. Morten has a vast experience as a pharmaceutical executive and have worked at senior positions at different life sciences companies. Apart from Mr. Brandt, the company has also appointed Dr. Thoralf Schlosser as the Qualified Person for the company’s European Medical Division. The company’s pharmacokinetic study also recently received the European Union Drug Regulating Authority Clinical Trial (EudraCT) number and Protocol Code Number.

The study examines the potential increase in cannabinoids bioavailability using the company’s exclusive VesiSort patented Technology.

Continue Reading
Advertisement

BUSINESS

Dosecann Inc, A Subsidiary Of Auxly Cannabis Group Inc (OTCMKTS:CBWTF), Enters A Pact With Lonza Group AG (OTCMKTS:LZAGF) For LEMS Machine And Capsule Filling And LEMS Technology

Published

on

Auxly Cannabis Group Inc (OTCMKTS:CBWTF)’s subsidiary Dosecann Inc has signed a pact with Lonza Group AG (OTCMKTS:LZAGF)’s subsidiary Capsugel Inc. As per the terms of the accord, Dosecann receives rights to use sealing LEMS and capsule filling LEMS technology. The company also gets equipment for capsule sealing and filling besides proprietary liquid filled Licaps capsules of Lonza. Dosecann collaborates with Lonza for new formulations to produce Cannabis capsules.

Lonza’s technology in health applications

Lonza’s technology is used in functional improvements such as odor and taste masking, bioavailability enhancement, controlled/ delayed release, and combination products in nutritional and health applications.

Annual capacity for 200 million capsules

Dosecann will equip its PEI facility with a complete production line having an annual capacity to fill/ seal 200 million Capsugel Licaps capsules. It can provide new compounds having improved functionality.

Dosecann will improve its production and product development capabilities by getting access to patented technologies of Lonza. The company will also use the patented technology to support the differentiated product offerings via possibilities of color and branding and multiple delivery systems. The new technologies of Lonza will enable Dosecann to introduce differentiated and innovative capsule products in different dosages.

President of Auxly, Hugo Alves said the company is thrilled to work with an international leader in encapsulation technology and capsules. He looks forward to develop a fruitful and creative long-term relationship with Capsugel and Lonza. It is the right time for the deal because Auxly is preparing to market derivative products with expected legalization by end of this year.

Auxly focuses marijuana derivatives

Auxly is focusing on marijuana derivatives expansion by end of this year despite widening its net loss. The company has reported revenues of $817,000 CAD in Q1 2019. The company has derived sales of $525,000 CAD from deferred service contracts contributed by KGK Sciences. It has generated balance sales of $292,000 CAD from cannabis flower. The company is holding back the dried flower to produce concentrates, edibles, and topicals expecting legalization by Health Canada by October 2019. Its net loss has widened to $13.8 million CAD in Q1 2019 from $10.5 million CAD in Q1 2018.

Continue Reading

BUSINESS

Real Brands Inc (OTCMKTS:RLBD) Signs An LOI To Purchase Proprietary CBD Formulas From Florida Based Integrative Medicine US

Published

on

Real Brands Inc (OTCMKTS:RLBD) has signed an LOI to buy proprietary CBD formulas of Integrative Medicine US. The formulas comprise ancient Chinese Medicine and Herbal Remedies that are blended CBD, nutrients, and endocannabinoid systems. Following the acquisition, Real Brands will use the formulas in its CBD Pharmacy brand. The company will use the new logo with a Chinese Symbol of healing.

CBD Pharmacy products

The initial product launch of CBD Pharmacy comprise salves, tinctures, balms, powders, and capsules developed to treat pain and promote relaxation, and boost immunity and energy.

Jerry Pearring, Chief Executive Officer of Real Brands, said medicinal herbs, CBD, and vitamins are blended using a proprietary formula to develop innovative medicine by Jonathan M. Fields, the founder of Integrative Medicine. The new products will help to keep the Real Brands in the driver’s seat to create a strong brand for CBD Pharmacy.

According to Pearring, CBD Pharmacy is expected to satisfy the growing consumer demand for hemp derived cannabidiol products. Consumers will also enjoy the benefits of eastern medical therapies.

Jonathan said the recent technological advances helped the company to develop superior medicinal products. Its features include Vegan, 100% Non-GMO, and tested in a third-party lab using cannabidiol. The company developed delivery mechanisms so that customers can get CBD and other ingredients in the right dosage to provide the desired effect for long-time.

Partners with Scot Piercy

Real Brands has partnered with Scot Piercy, a professional athlete, in April 2019. He will act as an ambassador for Real Brands Team and invested in the company last month. Pearring commenting the partnership said the company is excited to announce Scot as an ambassador. The investment shows the belief in the business model of the company and the long-term prospects. Pearring is pleased to welcome Scot on board Real Brands.

Piercy said he is proud to join the team of Real Brands. He studied about Real Brands and provides the support to grow hemp derived cannabidiol brands. Piercy further said it is looking forward to work with the company to introduce unique brands of Real Brands through e-commerce sites and retail channels.

Continue Reading

BUSINESS

Hexo Corp (NYSEAMERICAN:HEXO) Acquisition Of Newstrike Brands Finalized

Published

on

Acquisition now Finalized

Hexo Corp (NYSEAMERICAN:HEXO) has announced that it has completed the acquisition of all of Newstrike Brands’ issued and outstanding securities totaling 558,971, 064 marking the finalization of the acquisition process. The company has also received regulatory approval from relevant authorities including the high court further stamping the deal.

Reportedly, Newstrike Brands’ board of directors voted enthusiastically in favor of the acquisition that saw each of Newstrike’s stock exchanged for 0.06332 of Hexo’s share. Following the completion of the acquisition process, is expected to be delisted from TSX exchange platform as it will now operate under its new owner- Hexo.

Increased Production Space and Capacity

Popular voices in the industry believe that the $263 million acquisition sets Hexo among the industry’s elite. Among the several befits Hexo stands to gain from the acquisition includes additional production space estimated at 470,000 sqft. This is a significant addition to the company’s existing 1.3 million sqft.

With additional growing space comes increased production capacity. It is estimated that Hexo’s annual production capacity will surge from the current 110,000 kilos annually to a whopping 150,000 kilos annually which obviously translates to revenue influx.

Hexo’s CEO, Sebastien St-Louis said that “The combination of these two talented teams, both pioneers in the cannabis industry, will accelerate Hexo’s vision of creating the best cannabis technology company.” He adds that the Hexo is now commencing journey on the next phase of its progress.

The acquisition enhances the company’s solid position in the Canadian cannabis space and opening it up to countless possibilities abroad. The company already announced plans to set up operation in Greece as it seeks to seize the upcoming European market. Plans are also underway to set up operations in South America, the U.S (which is expected to open up fully by 2020), and more other locations.

The company already adjusted its 2020 revenue outlook to an optimistic $400 million. This projection factors in the company’s now bigger size in terms of production capacity and market access considering Hexo now assumes Newstrike’s distribution agreements with strategic partners across 8 Canadian provinces.

Continue Reading
Advertisement
Advertisement
Advertisement






Trending Stories